ZA200109263B - Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting. - Google Patents

Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting.

Info

Publication number
ZA200109263B
ZA200109263B ZA200109263A ZA200109263A ZA200109263B ZA 200109263 B ZA200109263 B ZA 200109263B ZA 200109263 A ZA200109263 A ZA 200109263A ZA 200109263 A ZA200109263 A ZA 200109263A ZA 200109263 B ZA200109263 B ZA 200109263B
Authority
ZA
South Africa
Prior art keywords
carboxylic acid
acid amides
adenosine uptake
uptake inhibiting
phenylcyclohexane carboxylic
Prior art date
Application number
ZA200109263A
Other languages
English (en)
Inventor
Wolf-Dietrich Freund
Stephen Lensky
Muller Stephan Nicholas
Holger Paulsen
Jorg Keldenich
Ervin Horvath
Joachim Schumacher
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA200109263B publication Critical patent/ZA200109263B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200109263A 1999-05-29 2001-11-09 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting. ZA200109263B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924818A DE19924818A1 (de) 1999-05-29 1999-05-29 Substituierte Phenylcyclohexancarbonsäureamide

Publications (1)

Publication Number Publication Date
ZA200109263B true ZA200109263B (en) 2003-01-29

Family

ID=7909712

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109263A ZA200109263B (en) 1999-05-29 2001-11-09 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting.

Country Status (36)

Country Link
US (2) US6716849B1 (no)
EP (1) EP1185516B1 (no)
JP (1) JP2003500475A (no)
KR (1) KR20020003397A (no)
CN (1) CN1200932C (no)
AR (1) AR024100A1 (no)
AT (1) ATE238997T1 (no)
AU (1) AU765752B2 (no)
BG (1) BG106107A (no)
BR (1) BR0011061A (no)
CA (1) CA2375186A1 (no)
CZ (1) CZ20014288A3 (no)
DE (2) DE19924818A1 (no)
DK (1) DK1185516T3 (no)
EE (1) EE200100634A (no)
ES (1) ES2197870T3 (no)
GT (1) GT200000083A (no)
HK (1) HK1048810A1 (no)
HN (1) HN2000000072A (no)
HR (1) HRP20010955A2 (no)
HU (1) HUP0201350A3 (no)
IL (1) IL146392A0 (no)
MA (1) MA25414A1 (no)
MX (1) MXPA01012241A (no)
MY (1) MY122576A (no)
NO (1) NO20015810L (no)
PE (1) PE20010167A1 (no)
PL (1) PL352101A1 (no)
PT (1) PT1185516E (no)
RU (1) RU2246490C9 (no)
SI (1) SI1185516T1 (no)
SK (1) SK17052001A3 (no)
SV (1) SV2004000087A (no)
UA (1) UA73126C2 (no)
WO (1) WO2000073275A1 (no)
ZA (1) ZA200109263B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1834090B (zh) * 2005-03-18 2011-06-29 中国科学院上海药物研究所 苯并咪唑类化合物、其制备方法以及用途
AU2009259440B2 (en) * 2008-06-16 2014-05-29 Boehringer Ingelheim International Gmbh Method for producing an intermediate product of dabigatran etexilate
JP6359008B2 (ja) 2012-06-11 2018-07-18 ユーシービー バイオファルマ エスピーアールエル Tnf−アルファ調節ベンゾイミダゾール
BR112021009988A2 (pt) * 2018-11-25 2021-08-17 Tnt Medical Corporation composto de fórmula (i), ou um n-óxido deste, ou um sal, solvato, polimorfo, tautômero, estereoisômero farmaceuticamente aceitável, uma forma isotópica, ou um pró-fármaco do dito composto de fórmula (i) ou n-óxido deste, composição farmacêutica, e método de tratamento de uma doença neoplásica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685918B1 (fr) * 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
ATE174913T1 (de) * 1992-07-31 1999-01-15 Bristol Myers Squibb Co Diphenyl oxazole-, thiazole- und imidazole- derivate als inhibitoren der wiederaufnahme des adenosins
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
HRP960015B1 (en) * 1995-02-01 2000-12-31 Bayer Ag Substituted indole derivatives
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden

Also Published As

Publication number Publication date
CZ20014288A3 (cs) 2002-03-13
EP1185516B1 (de) 2003-05-02
AU4405500A (en) 2000-12-18
HUP0201350A3 (en) 2003-05-28
HUP0201350A2 (en) 2002-08-28
ATE238997T1 (de) 2003-05-15
US6716849B1 (en) 2004-04-06
JP2003500475A (ja) 2003-01-07
RU2246490C9 (ru) 2005-09-20
DK1185516T3 (da) 2003-08-11
NO20015810L (no) 2002-01-25
CA2375186A1 (en) 2000-12-07
SK17052001A3 (sk) 2002-06-04
CN1365356A (zh) 2002-08-21
HN2000000072A (es) 2001-02-02
HRP20010955A2 (en) 2003-08-31
UA73126C2 (en) 2005-06-15
BG106107A (bg) 2002-05-31
DE50001982D1 (de) 2003-06-05
RU2246490C2 (ru) 2005-02-20
CN1200932C (zh) 2005-05-11
AR024100A1 (es) 2002-09-04
MY122576A (en) 2006-04-29
MA25414A1 (fr) 2002-04-01
SV2004000087A (es) 2004-05-07
MXPA01012241A (es) 2002-08-12
PL352101A1 (en) 2003-07-28
SI1185516T1 (en) 2003-10-31
IL146392A0 (en) 2002-07-25
KR20020003397A (ko) 2002-01-12
PT1185516E (pt) 2003-09-30
PE20010167A1 (es) 2001-04-25
US20040186106A1 (en) 2004-09-23
ES2197870T3 (es) 2004-01-16
HK1048810A1 (zh) 2003-04-17
EP1185516A1 (de) 2002-03-13
NO20015810D0 (no) 2001-11-28
EE200100634A (et) 2003-02-17
WO2000073275A1 (de) 2000-12-07
GT200000083A (es) 2001-11-17
DE19924818A1 (de) 2000-11-30
AU765752B2 (en) 2003-09-25
BR0011061A (pt) 2002-03-05

Similar Documents

Publication Publication Date Title
GB2351077B (en) Improved acid corrosion inhibitor
ZA99567B (en) Aryl-acrylic acid esters.
GB9923804D0 (en) Electronic commerce system
GB2357664B (en) Electronic commerce system
MXPA02003669A (es) Modificacion del tiempo de floracion.
EP1318726A4 (en) CLEANING AGENTS FOR MARINADES
MXPA03005151A (es) Sistema de sujecion magnetica.
HK1054038A1 (en) Substituted n-benzyl-indol-3-yl gloyoxylic acid derivatives having an antitumural effect
HK1034969A1 (en) Dihydroxyhexanoic acid derivatives.
ZA979756B (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors.
MXPA01012714A (es) Sistema de comercio electronico.
ZA200109263B (en) Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting.
MXPA01007977A (es) Complemento alimenticio de cromo-acido carboxilico.
ZA200108894B (en) Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitors.
ZA974033B (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors.
AP2004003005A0 (en) Novel alpha-oxygenated or alpha-thiolated carboxylic acid penethylamide derivatives.
HK1045740A1 (en) E commerce system.
ZA200003617B (en) Trailer noseweight indicator.
IL149237A0 (en) Electronic commerce system
ZA987000B (en) Tow bar.
ZA200106546B (en) Chromium-carboxylic acid free supplement.
ZA200006202B (en) Electronic commerce system.
GB9912903D0 (en) Fold-away tow bar
GB0026419D0 (en) Carboxylic acid complexes
ZA200000221B (en) Trailer.